Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities

Journal of Infectious Diseases

Volumn 211, Issue 12, 2015, Pages 1915-1924

  Nace, David A ^a   Lin, Chyongchiou Jeng ^b   Ross, Ted M ^c   Saracco, Stacey ^a   Churilla, Roberta M ^a   Zimmerman, Richard K ^b  

^a Division of Geriatric Medicine   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Vaccine and Gene Therapy Institute of Florida   (United States)

Author keywords

high dose influenza vaccine; inactivated influenza vaccine; long term care

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; VIRUS ANTIBODY;

AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; FRAIL ELDERLY; GEOMETRIC MEAN TITER; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NURSING HOME PATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROPROTECTION; SINGLE BLIND PROCEDURE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; VIRUS STRAIN; BLOOD; COMPARATIVE STUDY; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INFLUENZA, HUMAN; LONG TERM CARE;

AGED, 80 AND OVER; ANTIBODIES, VIRAL; FEMALE; FRAIL ELDERLY; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LONG-TERM CARE; MALE; SINGLE-BLIND METHOD;

EID: 84930324616     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu622     Document Type: Article

References (41)

1. Centers for Disease C, Prevention. Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010; 59:1057-62.
2. ThompsonWW, Shay DK,Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the united states. JAMA 2003; 289:179-86.
3. Carroll N, Delafuente J, McClure K, Weakley D, Khan Z, Cox F. Economic burden of influenza-like illness in long-term-care facilities. Am J Health Syst Pharm 2001; 58:1133-8.
4. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: A quantitative review. Vaccine 2006; 24:1159-69.
5. Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD. Cochrane re-arranged: Support for policies to vaccinate elderly people against influenza. Vaccine 2013; 31:6030-3.
6. Aspinall R, Del Giudice G, Effros RB, Grubeck-Loebenstein B, Sambhara S. Challenges for vaccination in the elderly. Immun Ageing 2007; 4:1807-14.
7. Grubeck-Loebenstein B, Della Bella S, Iorio AM, Michel J-P, Pawelec G, Solana R. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res 2009; 21:201-9.
8. NaceDA, Drinka P, Mann J, Poland GA. LTCinformation series: immunization in the long-term care setting. 2nd ed. Columbia,MD: AMDA, 2010.
9. Parodi V, Florentiis D, Martini M, Ansaldi F. Inactivated Influenza Vaccines. Drugs Aging 2011; 28:93-106.
10. Treanor JJ, Schiff GM, Couch RB, et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis 2006; 193:1223-8.
11. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166:1121-7.
12. Couch RB, Winokur P, Brady R, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007; 25:7656-63.
13. Cate TR, Rayford Y, Niño D, et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010; 28:2076-9.
14. Sullivan SJ, Jacobson R, Poland GA. Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine. Expert Rev Vaccines 2010; 9:1127-33.
15. Chen WH, Cross AS, Edelman R, Sztein MB, Blackwelder WC, Pasetti MF. Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine. Vaccine 2011; 29:2865-73.
16. Della Cioppa G, Nicolay U, Lindert K, et al. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59® adjuvant: Results from a dose-finding clinical trial in older adults. Hum Vaccin Immunother 2012; 8:216-27.
17. Moro PL, Arana J, Cano M, et al. Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010. Clin Infect Dis 2012; 54:1608-14.
18. DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: Safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine 2013; 31:861-6.
19. Palache AM, Beyer WEP, Sprenger MJW, et al. Antibody-response after influenza immunization with various vaccine doses - a double-blind, placebo-controlled, multicenter, dose-response study in elderly nursing-home residents and young volunteers. Vaccine 1993; 11:3-9.
20. Gallo JJ, Fulmer T, Paveza GJ, ReichelW. Handbook of geriatric assessment. 3rd ed. Gaithersburg, MD: Aspen Publishers, 2000.
21. Abellan van Kan G, Rolland Y, Andrieu S, et al. Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging 2009; 13:881-9.
22. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA 2011; 305:50-8.
23. Gillim-Ross L, Subbarao K. Emerging respiratory viruses: challenges and vaccine strategies. Clin Microbiol Rev 2006; 19:614-36.
24. Ross TM, Xu Y, Bright RA, Robinson HL. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 2000; 1:127-31.
25. Mitchell J. Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 2003; 21:902-14.
26. Bright RA, Ross TM, Subbarao K, Robinson HL, Katz JM. Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. Virology 2003; 308:270-8.
27. Bright RA, Medina M-J, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366:1175-81.
28. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295:891-4.
29. Nauta J. Statistics in clinical vaccine trials. Berlin: Springer-Verlag, 2010.
30. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200:172-80.
31. McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 2005; 23(suppl 1):S10-25.
32. Centers for Disease Control and Prevention. Seasonal influenza (flu): the flu season, 2013. http://www.cdc.gov/flu/about/season/flu-season. htm. Accessed 20 February 2014.
33. Skowronski DM, Tweed SA, Tweed SA, De Serres G. Rapid decline of influenza vaccine - induced antibody in the elderly: is it real, or is it relevant? J Infect Dis 2008; 197:490-502.
34. Song JY, Cheong HJ, Hwang IS, et al. Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence. Vaccine 2010; 28:3929-35.
35. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011; 204:1879-85.
36. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. New Eng J Med 2014; 371:635-45.
37. Wood JM, Gaines-Das RE, Taylor J, Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine 1994; 12:167-74.
38. Stephenson I, Heath A, Major D, et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis 2009; 15: 1252-9.
39. Greenspan S, Nace D, Perera S, et al. Lessons learned from an osteoporosis clinical trial in frail long-term care residents. Clin Trials 2012; 9:247-56.
40. Loeb M, Carusone SC, Goeree R, et al. Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia: a randomized controlled trial. JAMA 2006; 295:2503-10.
41. Kiel DP, Magaziner J, Zimmerman S, et al. Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial. JAMA 2007; 298:413-22.